Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Novatti Group - Appendix 4C and Quarterly Update (ASX:NOV)

To view the update, download the attached PDF.

Noxopharm - First COVID-19 Patient Treated in Veyonda Study (ASX:NOX)

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce the enrolment and treatment of the first patient into the Phase 1 NOXCOVID-1 study examini...read more

Noxopharm Announces Veyonda COVID-19 Study Approved For Immediate Start (ASX:NOX)

Australian drug development companyNoxopharm Limited (ASX: NOX) today announces the commencement of a clinical study of Veyonda® in COVID-19 patients. Following review by expert panels, official...read more

Noxopharm Announces Peer-Reviewed Publication Strengthens Case for Veyonda (ASX:NOX)

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce the publication of the first manuscript of the LuPIN trial in the journal, European Urology Onco...read more

Noxopharm Announces Data Shows Idronoxil Holds Key to Problem of COLD Cancers (ASX:NOX)

Important pre-clinical data from two independent research groups confirms that idronoxil (IDX), the active ingredient in Veyonda, achieves a major goal in restoring cancer-fighting immune function w...read more

Nyrada Brain Injury Drug Pharmacokinetic Study Results (ASX:NYR)

Nyrada Inc (ASX: NYR) reports results from a preclinical pharmacokinetic study of its two lead Brain Injury drug candidates. Both candidates have achieved durable therapeutic levels when administere...read more

Nyrada Cholesterol-Lowering Drug Study Results (ASX:NYR)

Nyrada Inc (ASX: NYR) is pleased to report encouraging preclinical results from its cholesterol-lowering program to develop a drug to treat hypercholesterolemia. A study using healthy donor human...read more

NetLinkz - Voluntary Suspension (ASX:NET)

The securities of Netlinkz Limited (‘NET’) will be suspended from quotation immediately under Listing Rule 17.2, at the request of NET, pending the release of an announcement regarding a...read more

Noxopharm Announces COVID-19 Trial Program to Commence in Europe (ASX:NOX)

NOX announces commencement of its NOXCOVID clinical program with a planned Phase 1 trial in Europe. This action is designed to provide important safety data and proof-of-principle of Veyonda as a po...read more

NetLinkz Announces Trading Halt (ASX:NET)

The securities of Netlinkz Limited (‘NET’) will be placed in trading halt at the request of NET, pending it releasing an announcement regarding a capital raising. Unless ASX decides othe...read more

NetLinkz - S&P DJI Announces June 2020 Quarterly Rebalance (ASX:NET)

S&P Dow Jones Indices announced today the changes in the S&P/ASX indices, effective at the open of trading on June 22, 2020. At this rebalance, the entire S&P/ASX index hierarchy is revi...read more

Noxopharm Announces ASCO 2020 Highlights NOX66 Potential in Late-Stage Cancer (ASX:NOX)

Noxopharm (ASX: NOX) today reports on the public release at a global oncology conference of 2 sets of clinical data relating to the development of NOX66 (Veyonda®) as a treatment of end-stage ca...read more

NetLinkz - Pause in trading (ASX:NET)

Trading in the securities of the entity will be temporarily paused pending a further announcement. For more information, download the attached PDF.

Milestone Achieved in the Nyrada Brain Injury Program (ASX:NYR)

Nyrada Inc (ASX: NYR) provides an update on one of its leading programs for treatment of brain injury. Nyrada has shown in a preclinical pharmacokinetic study that its lead candidate compounds ca...read more

Noxopharm announces FDA allows Veyonda Pre-IND Submission for COVID-19 (ASX:NOX)

Noxopharm (ASX:NOX) today announces that on advice from the U.S. Food and Drug Administration (FDA), the Company has lodged a pre-Investigational New Drug (pre-IND) submission for a clinical trial o...read more

Viewing: 1 - 15 of 200 Previous | Next